CN106488774B - 人源化抗-tf-抗原抗体 - Google Patents

人源化抗-tf-抗原抗体 Download PDF

Info

Publication number
CN106488774B
CN106488774B CN201580027114.8A CN201580027114A CN106488774B CN 106488774 B CN106488774 B CN 106488774B CN 201580027114 A CN201580027114 A CN 201580027114A CN 106488774 B CN106488774 B CN 106488774B
Authority
CN
China
Prior art keywords
antibody
jaa
mouse
cells
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580027114.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN106488774A (zh
Inventor
凯特·里顿豪斯-奥尔森
朱莉娅·阿布杜拉
静·英·恩格
斯蒂芬·T.·康瑞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of CN106488774A publication Critical patent/CN106488774A/zh
Application granted granted Critical
Publication of CN106488774B publication Critical patent/CN106488774B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201580027114.8A 2014-04-18 2015-04-20 人源化抗-tf-抗原抗体 Active CN106488774B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461981240P 2014-04-18 2014-04-18
US61/981,240 2014-04-18
PCT/US2015/026595 WO2015161311A2 (en) 2014-04-18 2015-04-20 Humanized anti-tf-antigen antibodies

Publications (2)

Publication Number Publication Date
CN106488774A CN106488774A (zh) 2017-03-08
CN106488774B true CN106488774B (zh) 2019-11-01

Family

ID=54324717

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580027114.8A Active CN106488774B (zh) 2014-04-18 2015-04-20 人源化抗-tf-抗原抗体

Country Status (12)

Country Link
US (1) US11130821B2 (enExample)
EP (2) EP3797793A1 (enExample)
JP (1) JP6740135B2 (enExample)
KR (1) KR102413809B1 (enExample)
CN (1) CN106488774B (enExample)
AU (1) AU2015247358B2 (enExample)
BR (1) BR112016024214B8 (enExample)
CA (1) CA2943681A1 (enExample)
ES (1) ES2843546T3 (enExample)
MX (2) MX378944B (enExample)
RU (1) RU2699717C2 (enExample)
WO (1) WO2015161311A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201908813QA (en) * 2017-04-13 2019-10-30 Aduro Biotech Holdings Europe B V Anti-sirp alpha antibodies
TWI826393B (zh) * 2017-09-22 2023-12-21 美商免疫遺傳股份有限公司 使用陽離子交換層析法分離三輕鏈抗體
SG11202009308WA (en) * 2018-03-28 2020-10-29 Mitsubishi Tanabe Pharma Corp DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF
WO2019231957A1 (en) * 2018-05-30 2019-12-05 National Health Research Institutes Anti-abeta antibodies and uses thereof
CA3122899A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
KR20210107062A (ko) 2018-12-21 2021-08-31 오제 이뮈노테라프틱스 이작용성 항-PD-1/SIRPα 분자
BR112021011982A2 (pt) 2018-12-21 2021-09-14 Ose Immunotherapeutics Anticorpo anti-humano-pd-1 humanizado
CA3123338A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CA3172697A1 (en) * 2020-03-23 2021-09-30 Ruth Yin-Zong LAN Anti-ccr8 antibodies for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260680A1 (en) * 2004-04-16 2005-11-24 Vanderbilt University Methods of diagnosing and treating autoimmune diseases
CA2582252C (en) 2004-07-26 2014-08-26 The Research Foundation Of State University Of New York Therapeutic use of anti-tf-antigen antibody
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
AU2007226863A1 (en) * 2006-03-21 2007-09-27 Wyeth Methods for preventing and treating amyloidogenic diseases
EP2161031A1 (en) * 2008-09-05 2010-03-10 SuppreMol GmbH Fc gamma receptor for the treatment of B cell mediated multiple sclerosis
PL2488551T3 (pl) * 2009-10-16 2019-01-31 Progastrine Et Cancers S.À R.L. Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania
EP2347769A1 (en) * 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
JP2014514314A (ja) * 2011-04-20 2014-06-19 ゲンマブ エー／エス Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
BR112014013081A2 (pt) * 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha veículo contendo fármaco em célula para formação de um complexo imune
CN102796144A (zh) * 2012-08-22 2012-11-28 山东大学 Tf抗原及其类似物、和其化学酶法合成方法及其应用
US10023651B2 (en) * 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies

Also Published As

Publication number Publication date
EP3131581A2 (en) 2017-02-22
CA2943681A1 (en) 2015-10-22
BR112016024214B8 (pt) 2023-12-26
BR112016024214B1 (pt) 2023-11-14
KR102413809B1 (ko) 2022-06-28
AU2015247358A1 (en) 2016-11-10
EP3797793A1 (en) 2021-03-31
MX2016013686A (es) 2017-03-31
US20180258182A1 (en) 2018-09-13
EP3131581B1 (en) 2020-09-23
RU2016143552A (ru) 2018-05-21
CN106488774A (zh) 2017-03-08
WO2015161311A3 (en) 2015-12-10
AU2015247358B2 (en) 2020-02-27
RU2016143552A3 (enExample) 2018-11-14
BR112016024214A2 (pt) 2018-01-23
ES2843546T3 (es) 2021-07-19
MX2021000439A (es) 2021-03-25
JP2017518260A (ja) 2017-07-06
WO2015161311A2 (en) 2015-10-22
RU2699717C2 (ru) 2019-09-09
EP3131581A4 (en) 2018-02-21
KR20170010356A (ko) 2017-01-31
JP6740135B2 (ja) 2020-08-12
MX378944B (es) 2025-03-10
US11130821B2 (en) 2021-09-28

Similar Documents

Publication Publication Date Title
CN106488774B (zh) 人源化抗-tf-抗原抗体
JP2022137018A (ja) 特異的結合タンパク質およびこれらの使用
US11427648B2 (en) Anti-CD146 antibodies and uses thereof
AU2005226799A1 (en) Cytotoxicity mediation of cells evidencing surface expression of CD63
CN114401744B (zh) 用于治疗癌症的抗cd33抗体
JP6947435B2 (ja) 炭酸脱水素酵素に結合する抗体およびその用途
CN114341176A (zh) Cd19抗体及其使用方法
US20170129954A1 (en) Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis
TW202417489A (zh) 使用抗ｃｌｄｎ１８．２抗體—放射性核種結合物之非侵入性方法
US10023651B2 (en) Humanized anti-TF-antigen antibodies
KR101380057B1 (ko) 췌장암의 진단제 및 치료제
HK40042631A (en) Humanized anti-tf-antigen antibodies
JP2020524527A (ja) ヒト腫瘍幹細胞をターゲティングするモノクローナル抗体及びその使用
JP2017024991A (ja) 抗カドヘリン１７抗体及び胃がん体外イメージング剤
HK1233512B (en) Humanized anti-tf-antigen antibodies
JP2024540374A (ja) がん胎児性抗原に対するモノクローナル抗体、及びそれらの使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant